Replies to post #98609 on PharmaCyte Biotech Inc (PMCB)

[DragonBear]

this tech would be valued in the billions-LOL

Probably the total revenue for 2nd line PC Chemo is $100M at most total. So some acquirer is going to pay $Bs, for pre-clinical data, and not even an IND? No CT data. Likely to fail in a mythical Phase 1 CT. There's nothing of tech value there to justify $Bs. Not enough to justify a PPS of 0.03. But what about diabetes? So, what about it? Not even any pre-clinical of Melligen cells wrapped in CIABs. No pouch or container to place the CIABs, containing cells derived from a cancerous liver cell line. What value?

The idea someone is going to pay $Bs for PMCB, where the acquisition cost will never come close to being recoverable is comical.